GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation

Helge C. DORFMUELLER, Vladimir S. BORODKIN, Marianne SCHIMPL and Daan M. F. VAN AALTEN
Division of Molecular Microbiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K.

INTRODUCTION

Reversible post-translational modification of many cytoplasmic and nuclear proteins in eukaryotic cells by glycosylation of serine and threonine residues with β-linked N-acetylglucosamine (O-GlcNAc) has been shown to play important roles in cellular processes as diverse as DNA transcription and translation, insulin sensitivity, protein trafficking and degradation [1–4]. Dysregulation of O-GlcNAc appears to play a role in human pathogenesis, such as cancer [5–7] and Alzheimer’s disease [8–12]. O-GlcNAc is also implicated in Type 2 diabetes [13,14]; however, the precise mechanism is still controversial [15].

In higher eukaryotes only two enzymes are responsible for the dynamic cycling of O-GlcNAc, the OGT (O-GlcNAc transferase; CAZY family GT41 [16]) which transfers GlcNAc on to proteins from the UDP-GlcNAc donor, and the OGA (O-GlcNAcase; CAZY family GH84 [17]), which catalyses the removal of O-GlcNAc. The precise molecular mechanisms by which OGT and OGA recognize and act on hundreds of proteins remain to be discovered [18].

Inhibition of hOGA (human OGA) with PUGNAc [O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenylcarbamate] (Figure 1A) (Ki = 50 nM [19,20]) has been used extensively to study the role of O-GlcNAc in a range of cellular processes [21–27]. Crystal structures of bacterial hOGA homologues have become available [28,29], and it has been shown that PUGNAc is a tight-binding inhibitor, with its imidolactone ring mimicking the half-chair/envelope conformation of the pyranose ring in the transition state by virtue of the stable oxime moiety [28,30]. However, PUGNAc also potently inhibits the human HexA/B (hexosaminidases A/B; CAZY family GH20) [31]. Structural analysis has revealed that the acetamido group leads to up to 160-fold selectivity against the human lysosomal hexosaminidases which employ a similar substrate-assisted catalytic mechanism. Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site. GlcNAcstatins are cell-permeant and, at low nanomolar concentrations, effectively modulate intracellular O-GlcNAc levels through inhibition of OGA, in a range of human cell lines. Thus these compounds are potent selective tools to study the cell biology of O-GlcNAc.

Key words: GlcNAcstatin, inhibition, O-GlcNAc, O-GlcNAcase.

O-GlcNAcylation is an essential, dynamic and inducible post-translational glycosylation of cytosolic proteins in metazoa and can show interplay with protein phosphorylation. Inhibition of OGA (O-GlcNAcase), the enzyme that removes O-GlcNAc from O-GlcNAcylated proteins, is a useful strategy to probe the role of this modification in a range of cellular processes. In the present study, we report the rational design and evaluation of GlcNAcstatins, a family of potent, competitive and selective inhibitors of human OGA. Kinetic experiments with recombinant human OGA reveal that the GlcNAcstatins are the most potent human OGA inhibitors reported to date, inhibiting the enzyme in the sub-nanomolar to nanomolar range. Modification of the GlcNAcstatin N-acetyl group leads to up to 160-fold selectivity against the human lysosomal hexosaminidases which employ a similar substrate-assisted catalytic mechanism. Mutagenesis studies in a bacterial OGA, guided by the structure of a GlcNAcstatin complex, provides insight into the role of conserved residues in the human OGA active site. GlcNAcstatins are cell-permeant and, at low nanomolar concentrations, effectively modulate intracellular O-GlcNAc levels through inhibition of OGA, in a range of human cell lines. Thus these compounds are potent selective tools to study the cell biology of O-GlcNAc.
concentrations. Furthermore, we report four new GlcNAcstatin derivatives that explore potency and selectivity of this scaffold, with one of these being the most potent hOGA inhibitor reported so far, inhibiting with a $K_i$ of 420 pM. Guided by a crystal structure of one of these derivatives in complex with a bacterial OGA, we probe key interactions through mutagenesis. These novel molecules will be useful tools for the study of OGA in a range of cellular signal transduction pathways.

**MATERIALS AND METHODS**

**Cloning, protein expression and purification**

The previously described plasmid for expression of the OGA orthologue from *CpOGA* (*Clostridium perfringens* OGA) [28] was used as a template to carry out mutagenesis of Val331 to cysteine, using the QuikChange® kit (Stratagene) with the following primers: 5′-GGGAGATGTAAAACCATTAATAACTTGCCCAACAGAGTATGATACTGGAGC-3′ and 5′-GCTCCAGTAATCTTCTGGGCA TGTTATTATA TGGTTTTACA TCTCCC-3′. W490A mutagenesis was performed using the same protocol and techniques with primers: 5′-GGACAATAAAACTGTGGCGGCTAAATCAGGAAG-3′ and 5′-CTTCCTGATTTAGCGCAGTT TTATTGTCC-3′. The constructs were verified by DNA-sequencing. V331C-CpOGA, W490A-CpOGA and wild-type protein were expressed and purified following the protocol described previously [28,41,43].

hOGA (amino acid residues 53–916) was cloned into a modified version of pGEX6P-1, lacking the BamHI site, and the hOGA sequence was inserted using EcoRI and NotI sites, after an internal EcoRI site was removed by introducing a silent mutation. The protein was expressed in *Escherichia coli* BL21 (DE3) cells overnight at 15°C using 10 μM IPTG (isopropyl β-D-thiogalactoside; $D_{osm}$ of 0.4–0.6). The cells were harvested by centrifugation (3500 g for 30 min at 4°C) and lysed with sonication in lysis buffer [50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% 2-mercaptoethanol, 0.2 mM PMSF and 1 mM benzamidine]. The recombinant GST (glutathione transferase)-fusion protein was bound to glutathione-Sepharose beads that were pre-equilibrated in washing buffer [50 mM Tris/HCl (pH 7.5), 250 mM NaCl, 1 mM EGTA, 0.1% 2-mercaptoethanol, 0.2 mM PMSF and 1 mM benzamidine]. The fusion protein was eluted using the washing buffer supplemented with 20 mM glutathione and the pH was adjusted to 7.5. The eluted protein was dialysed into 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 150 mM NaCl, 0.07% 2-mercaptoethanol, 0.1 mM PMSF and 1 mM benzamidine.

**Determination of the CpOGA–GlcNAcstatin D complex structure**

*CpOGA* was crystallized as described previously [28,41,43]. An aliquot of 1 μl of a suspension of GlcNAcstatin D in mother liquor was added to the crystallized protein in a 2.25 μl drop (1 μl of protein plus 1 μl of mother liquor plus 0.25 μl of 40% γ-butyrolactone). After 50 min at 20°C (room temperature) the crystal was cryoprotected by 5 s immersion in 0.17 M ammonium sulfate, 0.085 M sodium cacodylate (pH 6.5), 25.5% PEG [poly(ethylene glycol)] 8000 and 15% glycerol, and frozen in a nitrogen cryostream. Data were collected at the European Synchrotron Radiation Facility on beamline ID14-1 to 2.3 Å (1 Å = 0.1 nm), with an overall $R_{merge}$ of 0.074 and 98.2% completeness. Refinement was initiated from the native *CpOGA*–GlcNAcstatin C complex (PDB entry 2J62, [41]). Well-defined $F_w-F_c$ electron density for the inhibitor was observed.
GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation

Figure 2 Structural analysis of GlcNAcstatin derivatives and PUGNAc in complex with CpOGA

(A) Stereo view of GlcNAcstatin D (sticks with green carbon, red oxygen and blue nitrogen atoms) in the active site of CpOGA (sticks with grey carbon). Hydrogen bonds are indicated by black broken lines. Unbiased |Fo|–|Fc|, ϕcalc electron density map (2.75σ) is shown as a cyan chickenwire. (B) Stereo view of superimposed crystallographically determined complexes of CpOGA with GlcNAcstatin C (PDB number 2J62) (colour scheme as in A) and PUGNAc (PDB number 2CBJ) (sticks with light blue carbon), black broken lines showing hydrogen bonds for the CpOGA–GlcNAcstatin complex.

Figure 2A), allowing placement of an inhibitor model, built with the help of a PRODRG [44] structure and topology. Iterative model building using COOT [45] and refinement with REFMAC [46] yielded the final model with good statistics (R, Rfree:18.5, 23.8).

Inhibition measurements

Steady-state kinetics of wild-type hOGA and CpOGA mutants were determined using the fluorogenic substrate 4MU-NAG (4-methylumbelliferyl-N-acetyl-β-D-glucosaminide; Sigma). Standard reaction mixtures (50 μl) contained 2 pM CpOGA mutant in 50 mM citric acid, 125 mM Na2HPO4 (pH 5.5), 0.1 mg/ml BSA, and 1.5–25 μM of substrate in water. Steady-state kinetics of GlcNAcstatin C were performed in the presence of different concentrations of the inhibitor (0, 35, 70 and 140 pM). The reaction mixtures were incubated at 20°C for 466 min. For hOGA, the 50 μl standard reaction volume contained 2 nM hOGA–GST (53–916), McIlvaine buffer-system (0.2 M Na2HPO4 mixed with 0.1 M citric acid, pH 5.7), 0.1 mg/ml BSA, 0–250 μM 4MU-NAG with various GlcNAcstatin C concentrations (0, 10, 20 and 40 nM). The reaction was run for 60 min.

All reactions were stopped (before more than 10% of the substrate was consumed) by the addition of 100 μl of 3 M glycine/NaOH (pH 10.3). The fluorescence of the released 4-methylumbelliferone was quantified using a FLX 800 Microplate Fluorescence Reader (Bio-Tek), with excitation and emission wavelengths of 360 and 460 nm respectively. The mode of inhibition was visually verified by the Lineweaver–Burk plot (Figure 1B), and the K_i was determined by fitting all fluorescence intensity data to the standard equation for competitive inhibition in GraFit (Erithacus Software) (Tables 1 and 2). IC_{50} measurements with a mixture of human Hex A/B activities (purchased from Sigma, catalogue number A6152) against GlcNAcstatin A–E and PUGNAc were performed using the fluorogenic 4MU-NAG

<table>
<thead>
<tr>
<th>Compound</th>
<th>Hex A/B, K_i (nM)*</th>
<th>hOGA, K_i (nM)</th>
<th>Selectivity (GH20/hOGA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlcNAcstatin A</td>
<td>0.55 ± 0.05</td>
<td>4.3 ± 0.2</td>
<td>n.s.</td>
</tr>
<tr>
<td>GlcNAcstatin B</td>
<td>0.17 ± 0.05</td>
<td>0.42 ± 0.06</td>
<td>n.s.</td>
</tr>
<tr>
<td>GlcNAcstatin C</td>
<td>500 ± 10</td>
<td>4.4 ± 0.1</td>
<td>164</td>
</tr>
<tr>
<td>GlcNAcstatin D</td>
<td>2.7 ± 0.4</td>
<td>0.74 ± 0.09</td>
<td>4</td>
</tr>
<tr>
<td>GlcNAcstatin E</td>
<td>1100 ± 100</td>
<td>8500 ± 300</td>
<td>n.s.</td>
</tr>
<tr>
<td>PUGNAc</td>
<td>25 ± 2.5</td>
<td>35 ± 6*</td>
<td>n.s.</td>
</tr>
</tbody>
</table>

*The Cheng–Prusoff equation \( K_i = \frac{IC_{50}}{1 + \left(\frac{[S]}{K_m}\right)} \) was used to convert the IC_{50} values into an absolute inhibition constant (K_i).
substrate and standard reaction mixtures as described previously [41,43], with the following changes: 5 μ-units/ml enzyme mixture was used with a fixed substrate concentration at the $K_m$ (230 μM) in the presence of different concentrations of the inhibitors, 100 pM to 100 μM (GlcNAcstatins) and 10 pM to 1 nM (PUGNAc).

**Cell-based assays and Western blot analysis**

Cell lines were maintained in DMEM [Dulbecco’s modified Eagle’s medium; containing 1 g/l glucose for HEK (human embryonic kidney)-293 cells, and 4.5 g/l glucose for HeLa, HT-1080, SH-SY5Y and U-2 OS cells] supplemented with 10% (v/v) foetal bovine serum. Subconfluent cells were treated with various concentrations of inhibitors in the presence of 0.1% DMSO. After 6 h, cells were washed once in ice-cold PBS and harvested in the following lysis buffer: 50 mM Tris (pH 7.4), 0.27 M sucrose, 1 mM sodium orthovanadate, 1 mM EDTA, 1 mM EGTA, 10 mM sodium β-glycerophosphate, 50 mM NaF, 1% Triton X-100, 0.1% 2-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF and 5 μM leupeptin. Cell debris was removed by centrifugation (13000 × g for 10 min at 4 °C), and supernatants were analysed by immunoblotting. For Western blot analysis, 15–30 μg of total cellular protein was separated by SDS/PAGE, and O-GlcNAcylation was detected with the anti-O-GlcNAc antibody CTD1101.6. An anti-β-tubulin antisera was used as a loading control. The O-GlcNAc signal in each lane was quantified using the AIDA (Advanced Image Data Analyzer) software version 3.27, and normalized against the β-tubulin signal.

**RESULTS AND DISCUSSION**

**GlcNAcstatins: a new family of potent hOGA inhibitors**

Exploiting the available structural data of a complex of a *C. perfringens* OGA orthologue (CpOGA, [28,41]), GlcNAcstatins A–E were designed and synthesized (Figure 1A, details of synthesis to be reported elsewhere; for further details please contact the corresponding author). GlcNAcstatins A–E fall into two subfamilies, based on their modification on the C-2 position of the imidazole ring. GlcNAcstatin A carries the carboxymethyl group, whereas GlcNAcstatins B–E carry a phenylthio group. GlcNAcstatin C carries an isobutyl group instead of the smaller N-acetyl group in GlcNAcstatin A and B, GlcNAcstatin D an N-propionyl group, and GlcNAcstatin E an N-imidazole group. The increased length of the N-acetyl derivative was explored to determine the most useful substituent to specifically inhibit hOGA over the lysosomal Hexs.

**GlcNAcstatins are (sub)nanomolar inhibitors of hOGA**

A previous report on GlcNAcstatin C showed picomolar inhibition of an apparent hOGA orthologue from the bacterium *C. perfringens* (CpOGA) [41], whereas inhibition of hOGA remained to be explored. GlcNAcstatins A–E were tested in dose–response experiments against recombinant hOGA, with subsequent Lineweaver–Burk analysis revealing competitive inhibition against the enzymes (Table 1 and Figure 1B). GlcNAcstatins A–D inhibit the human enzyme in the low nanomolar to subnanomolar range (Table 1 and Figure 1B). GlcNAcstatins B and D are the most potent hOGA inhibitors with $K_i$ values of 0.4 and 0.7 nM respectively, being, to the best of our knowledge, the most potent hOGA inhibitors currently available. GlcNAcstatins A and C are equally potent with $K_i$ values of 4.3 nM and 4.4 nM respectively. GlcNAcstatin E inhibits only in the micromolar range.

**Tuning of hOGA/Hex selectivity**

All GlcNAcstatin derivatives were evaluated against human lysosomal Hexs to investigate their potential selectivity towards hOGA (Table 1 and Figure 1C). GlcNAcstatin A is the smallest GlcNAcstatin family member. It carries the N-acetyl moiety and the carboxymethyl group, and inhibits hOGA in the nanomolar range. Assaying lysosomal HexA/B shows that the compound equally potently inhibits the GH20 enzymes ($K_i$ of 550 pM (Table 1). The first modification we addressed was to substitute the carboxymethyl group to obtain GlcNAcstatin B, similar to previous work showing that a β-glycosidase from *C. saccharolyticum* is more potently inhibited with a phenylthio-substituted glucoimidazole [47]. Indeed, GlcNAcstatin B is approx. 10-fold more potent against hOGA ($K_i$ of 420 pM) than GlcNAcstatin A. However, it also inhibits HexA/B more potently, giving a $K_i$ of 170 pM (Table 1). The IC50 data show that GlcNAcstatin B is (to the best of our knowledge) also the most potent HexA/B inhibitor currently known, with a $K_i$ of 170 pM, followed by GlcNAcstatin A ($K_i$ of 550 pM). With these suitably potent inhibitors in hand we attempted to address selectivity by modifying the N-acetyl group. The addition of a single methyl group to obtain an N-propionyl sidechain (GlcNAcstatin D) already leads to different inhibition profiles between hOGA and human lysosomal HexA/HexB (Table 1), with a 15-fold reduction in inhibition of HexA/B. Further extension to an isobutyl group (GlcNAcstatin C) reduces HexA/B inhibition more than 200-fold, giving selectivities of 164-fold for hOGA, whereas incorporation of a larger imidazole group resulted in loss of both potency and selectivity (Table 1 and Figure 1C).

**Probing key GlcNAcstatin binding residues**

To further understand the structural basis for selectivity, we determined the crystal structure of CpOGA in complex with GlcNAcstatin D (Figure 2). These data show that GlcNAcstatin D binds deep into the active site of CpOGA, with the sugar moiety adopting a 4E conformation, and assuming the same conformation as observed for the GlcNAcstatin C complex [41]. Interestingly, the structural data point towards two active site residues that may play a key role in the surprisingly large difference in activity and selectivity of the GlcNAcstatins towards the hOGA/CpOGA and HexA/B. The only non-conserved residue near the N-acetyl binding pocket in CpOGA is Val131, corresponding to Cys215 in hOGA. Unbiased $I_F,−|IF,−|$ density of the GlcNAcstatin D complex defines that the N-propionyl group points towards this non-conserved Val131 and occupies a single defined conformation, interacting with the Cα,β carbons (Figure 2A). Furthermore, the phenyl moiety from GlcNAcstatin D is seen to interact with a solvent-exposed tryptophan residue (Trp149), similar to the phenyl moiety from PUGNAc and GlcNAcstatin C in the respective *CpOGA* complexes [28,41] (Figure 2B). From a sequence alignment between *CpOGA* and hOGA, it is not clear whether an equivalently positioned aromatic residue exists in the
We have explored a new family of potent and competitive OGA inhibitors, the GlcNAcstatins, based on the GlcNAc–imidazole scaffold. Based on structural analysis with GlcNAcstatin C [41] and GlcNAcstatin D in complex with CpOGA we can explain the potency of this inhibitor family. All GlcNAcstatins interact with the active site of OGAs forming at least eight conserved hydrogen bonds (Figures 2A and 2B), the pyranose ring adopts a favoured E conformation, and conserved interactions with Asp297 and Asn396 force the N2 substituent to adopt a conformation compatible with the proposed substrate-assisted catalytic mechanism [20,28,29], with the carbonyl oxygen approaching the sp² hybridized carbon to within 3.4 Å.

GlcNAcstatins A–D inhibit hOGA in the low-nanomolar to sub-nanomolar range, while CpOGA is inhibited in the low micromolar range, implying that there are some (minor) differences in the GlcNAc-binding pocket between hOGA and CpOGA, even though the active sites of these enzymes are almost identical as
assessed by sequence alignment [28]. We have identified two key active-site residues, Val311/Trp308, which are responsible for stronger interactions of GlcNAcStatins with CpgOGA compared with hOGA. It still remains unknown to what extent the GlcNAcStat aglycon can be modified in order to increase the binding affinity for the human active site, given the possible structural divergence between the human/bacterial enzymes in this area.

GlcNAcStatins are to the best of our knowledge the most potent competitive inhibitors of hOGA. They can be used in cell-based assays in nanomolar concentrations to increase cellular O-GlcNAc levels in vivo in a range of human cell lines. Thus GlcNAcStatins provide a valuable tool for functional investigations of this post-translational modification and its involvement in signalling pathways within the eukaryotic cell.

ACKNOWLEDGEMENTS

We thank the European Synchrotron Radiation Facility, Grenoble, for the time at beamline ID1-1. We thank Abdellatif El Halimi (University of Dundee, Cloning Service, DSTT) for cloning of the hOGA construct and Sharon Shepherd and Mark Dorward for protein expression and purification.

FUNDING

This work was supported by a Wellcome Trust Senior Fellowship and a Lister Institute for Preventive Medicine Research Prize. H.C.D. is supported by the College of Life Sciences Undergrad Studentship.

REFERENCES


226

© The Authors. Journal compilation © 2009 Biochemical Society

Downloaded from http://portlandpress.com/biochemj/article-pdf/420/2/221/658092/bj4200221.pdf by guest on 07 February 2021
GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation


Received 19 January 2009/26 February 2009; accepted 10 March 2009
Published as BJ Immediate Publication 10 March 2009, doi:10.1042/BJ20090110

© The Authors Journal compilation © 2009 Biochemical Society